| Cat. No. |
Product Name |
Information |
| PC-22158 |
BBC0403
BRD2 inhibitor
|
BBC0403 (BBC-0403) is a specific BRD2 inhibitor with binding Kd of 41.4 uM and 7.6 uM for BRD2 (BD1) and BRD2 (BD2), inhibits the NF-κB and MAPK signalling pathways and the progression of osteoarthritis pathogenesis. |
| PC-21985 |
CBP bromodomain inhibitor 29
CBP bromodomain inhibitor
|
CBP-IN-29 is a potent, selective CBP bromodomain inhibitor with IC50 of 2.2 nM, displays exquisite selectivity over BRD4(1) (IC50=23 uM) and the broader bromodomain family. |
| PC-21984 |
CBP bromodomain inhibitor 27
CBP bromodomain inhibitor
|
CBP-IN-27 is a potent, selective CBP bromodomain inhibitor with IC50 of 3.6 nM, displays exquisite selectivity over BRD4(1) (IC50=11 uM) and the broader bromodomain family. |
| PC-21739 |
ZL0590
BRD4 BD1 inhibitor
|
ZL0590 is a potent, orally active, BRD4 BD1-selective inhibitor with IC50 of 90 nM for human BRD4 BD1. |
| PC-21732 |
XL-126
BET BD1 inhibitor
|
XL-126 (XL126) is a potent BD1-selective BET inhibitor with SPR binding KD value of 8.9 nM, has 185-fold BD1/BD2 selectivity. |
| PC-21726 |
DUAL946
BET/HDAC inhibitor
|
DUAL946 is a sub-micromolar inhibitor of both BET and class I & IIb HDAC proteins with IC50 of 0.05/0.25/0.42/14.13/34.89 uM for BRD4/HDAC1/HDAC2/HDAC5/HDAC7/HDAC9, respectively. |
| PC-21330 |
MS436
BRD4 BD1 inhibitor
|
MS436 is a potent, selective BRD4 BD1 bromodomain inhibitor with Ki values of 30-50 nM, 10-fold selectivity over the BD2. |
| PC-21329 |
GSK023
BET BD1 inhibitor
|
GSK023 is a potent, selective BET BD1 domain inhibitor with pIC50 of 7.8 against BRD4 BD1, >100-fold selective over BD2. |
| PC-21303 |
CN210
BET bromodomain inhibitor
|
CN210 is a quinazoline-based BET family inhibitor with Kd value of 70 nM for BRD4 (BD1,2) and IC50 of 0.94 uM in MV4-11 viability assay. |
| PC-21267 |
Dual PI3K/BET 18DS
PI3K/BET inhibitor
|
Dual PI3K/BET 18DS is a potent, chimeric dual PI3K/BET bromodomain inhibitor, demonstrates high selectivity, nanomolar range cellular potency, and compelling in vivo efficacy. |
| PC-21167 |
GNE-234
|
GNE-234 is the negative control compound of the selective PBRM1(2) inhibitor GNE-235. |
| PC-21073 |
IV-275
BRG1/BRM inhibitor
|
IV-275 is a next-generation inhibitor of BRG1 and BRM bromodomains, inhibits SWI/SNF complex and enhances DNA damage and cell death in glioblastoma. |
